Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Intentional mixture of two or more micro-organisms – cells,...
Reexamination Certificate
2010-04-16
2011-12-20
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Intentional mixture of two or more micro-organisms, cells,...
C424S131100, C435S320100
Reexamination Certificate
active
08080241
ABSTRACT:
Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.
REFERENCES:
patent: 5023252 (1991-06-01), Hseih
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5856181 (1999-01-01), McCormick
patent: 6136307 (2000-10-01), Lee et al.
patent: 6245543 (2001-06-01), Drake et al.
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: 6455038 (2002-09-01), Lee et al.
patent: 6723316 (2004-04-01), Laquerre et al.
patent: 6774119 (2004-08-01), Wechsler et al.
patent: 6838279 (2005-01-01), Wechsler et al.
patent: 7731951 (2010-06-01), Coffey et al.
patent: 0 514 603 (1992-11-01), None
patent: 0 828 005 (1998-03-01), None
patent: WO 96/00007 (1996-01-01), None
patent: WO 97/12623 (1997-04-01), None
patent: WO 98/37031 (1997-10-01), None
patent: WO 97/45142 (1997-12-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 98/50063 (1998-11-01), None
patent: WO 99/08692 (1999-02-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/45783 (1999-09-01), None
patent: WO 9955910 (1999-11-01), None
patent: WO 99/67372 (1999-12-01), None
patent: WO 01/35970 (2001-05-01), None
Toyoizumi, Takane et al., “Combined Therapy with Chemotherapeutic Agents and Herpes Simplex Virus Type 1 ICP34.5 Mutant (HSV-1716) in Human Non-Small Cell Lung Cancer”,Human Gene Therapy, vol. 10:pp. 3013-3029 (1999).
Bouvet et al., “Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide”Gene Ther. 5:189-195 (1998).
Eloit et al., “High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes”J. Virol. 71(7):5375-5381 (1997).
Jooss et al., “Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung”Human Gene Ther. 7(13):1555-1566 (1996).
Wildner et al., “Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus thymidine kinase”Cancer Research59:410-413 (1999).
Diven et al., “An overview of poxviruses”J. Am. Acad. Dermatol. 44(1):1-16 (2001).
Slattery et al., “Milers' nodules complicated by erythema multiforme and graft-versus-host disease after allogenic hematopoietic stem cell transplantation for multiple myeloma”CID40:63-66 (2005).
Cascallo et al., “Deletion of VAI and VAII RNA Genes in the Design of Oncolytic Adenoviruses,”Human Gene Therapy, 17:929-940 (2006).
Thimmappaya et al., “Adenovirus VAI RNA is Required for Efficient Translation of Viral mRNAs at Late Times after Infection,”Cell, 31:543-551 (1982).
Andreansky, S.S., et al. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93(21):11313-11319.
Alemany, R. et al. (1999). Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6(1):21-25.
Barbacid, M. (1987). Ras genes. Annu Rev Biochem. 56:779-827.
Battcock et al., 2006, J. Virol. 80(9):4422-4430.
Beattie, E., et al. (1991). Vaccinia virus-encoded eIF-2α homolog abrogates the antiviral effect of interferon. Virology. 183(1):419-422.
Black, T.L., et al. (1993). Degradation of the interferon-induced 68,000-M(r) protein kinase by poliovirus requires RNA. J Virol. 67(2):791-800.
Bos, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49(17):4682-4689.
Boviatsis, E.J., et al. (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 5:323-321.
Carroll, N.M., et al. (1997). The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res. 69(2):413-417.
Cascallo et al., 2003, Cancer Res. 63:5544-5550.
Cassady, K.A., et al. (1998). The second-site mutation in the herpes simplex virus recombinants lacking the γ134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2α. J Virol. 72(9):7005-7011.
Chahlavi, A., et al. (1999). Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1(2):162-169.
Chang, H.W. and Jacobs, B.L. (1993). Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology. 194(2):537-547.
Chaubert, P. et al. (1994). K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol. 144(4):767-775.
Chong, K.L., et al. (1992). Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J. 11(4):1553-1562.
Chung, R.Y., et al. (1999). B-mybpromoter retargeting of herpes simplex virus γ34.5 gene-mediated virulence toward tumor and cycling cells. J Virol. 73(9):7556-7564.
Davies, M.V., et al. (1991). The effect of poliovirus proteinase 2Apro expression on cellular metabolism. Inhibition of DNA replication, RNA polymerase II transcription, and translation. J Biol.Chem. 266(22):14714-14720.
Davies, M.V., et al. (1993). The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J Virol. 67(3):1688-1692.
Farassati et al., Nat. Cell Biol. 3:745-750.
Gura, T. (1997). Systems for identifying new drugs are often faulty. Science. 278(5340):1041-1042.
Haig, D.M., et al. (1998). The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase. Immunology. 93(3):335-340.
Hall-Jackson, C.A., et al. (1998). Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target. Br J Cancer. 78(5):641-651.
He, B., et al. (1997). The γ134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA. 94(3):843-848.
Ikeda, K., et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 5(8):881-887.
Jagus, R., and Gray, M.M. (1994). Proteins that interact with PKR. Biochimie. 76(8):779-791.
Janes, P.W., et al. (1994). Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene. 9(12):3601-3608.
Katze, M.G., et al. (1987). Adenovirus VAI RNA complexes with the 68 000 Mr protein kinase to regulate its autophosphorylation and activity. EMBO J. 6(3):689-697.
Katze, M.G. (1995). Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol. 3(2):75-78.
Kawagishi-Kobayashi, M., et al. (1997). Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2α Mol Cell Biol. 17(7):4146-4158.
Khoobyarian, N., et al. (1975). Inhibition of melanoma growth in hamsters by type-2 adenovirus. J Surg Oncol. 7(5):421-425.
Kirn, D.H., and McCormick., F. (1996). Replicating viruses as selective cancer therapeutics. Mol Med Today 2(12):519-527.
Lee, J.M., and Bernstein, A. (1993). p53 muta
Coffey Matthew C.
Thompson Bradley G.
Li Bao
McKeon Meunier Carlin & Curfman LLC
Oncolytics Biotech Inc.
LandOfFree
Viruses for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viruses for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viruses for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293414